ONCY — Oncolytics Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $114.94m
- $104.41m
Annual cashflow statement for Oncolytics Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.5 | -26.3 | -24.8 | -27.8 | -31.7 |
| Depreciation | |||||
| Non-Cash Items | -0.219 | 4.33 | 0.697 | -2.86 | 0.782 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.21 | -0.908 | 0.391 | 1.76 | 3.54 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -22.1 | -22.4 | -23.4 | -28.4 | -27 |
| Capital Expenditures | -0.029 | -0.286 | -0.055 | -0.008 | -0.239 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -20.3 | 20.2 | — |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.029 | -0.286 | -20.4 | 20.2 | -0.239 |
| Financing Cash Flow Items | 38.3 | 32.9 | 12.6 | 10.3 | 6.92 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 39.8 | 33 | 12.2 | 32 | 6.64 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 17.1 | 10 | -29.6 | 23.2 | -19 |